- Associated Press - Monday, July 23, 2012

DISAPPOINTING DATA: In the latest setback in Alzheimer’s research, an experimental drug failed the first of four late-stage studies. The treatment didn’t slow mental or functional decline in patients with mild or moderate Alzheimer’s who carry a gene that increases the risk of the disease.

WHAT’S NEXT: Development partners Pfizer Inc. and Johnson & Johnson will continue three other late-stage tests of bapineuzumab. Two studies are in patients who don’t have the ApoE4 gene.

WHAT’S AT STAKE: There’s no treatment that does more than temporarily ease Alzheimer’s symptoms, which afflict about 5 million Americans.

Copyright © 2017 The Washington Times, LLC.

blog comments powered by Disqus


Click to Read More

Click to Hide